Oncology & Cancer

New immune-stimulating drug, with chemo, shrinks pancreas tumors

The results of an early-stage (phase 1b) clinical trial for pancreatic cancer show that an experimental therapy can control tumors well enough to make some patients eligible for surgery, according to data published in The ...

Oncology & Cancer

Antigen level signals response to chemo for pancreatic cancer

(HealthDay)—A drop in carbohydrate antigen (CA) 19-9 levels of more than 10 percent after two rounds of chemotherapy is associated with longer survival in patients with advanced pancreatic ductal adenocarcinoma (PDAC), ...

Oncology & Cancer

Metformin use may not improve pancreatic cancer survival

Metformin use did not improve survival of patients with pancreatic ductal adenocarcinoma (PDAC) in a retrospective cohort study, according to data presented at the AACR Annual Meeting 2015, April 18-22.

page 8 from 11